May. 5 at 1:56 PM
$MCRB 📊
$MCRB – Quick 8-K Summary (Q1 2026): Highly speculative biotech focused on microbiome (SER-155, SER-603). Key catalyst is SER-155 data expected in the coming weeks, but trial is very small (15 patients) → binary outcome. Financials show net loss of -
$19.9M with ~
$29.8M cash and runway until Q3 2026, so dilution is likely. No solid recurring revenue and company remains dependent on clinical results and funding. Scenarios: Bull
$12–18+, Bear
$4–6, Neutral
$6–9. Overall this is a pure news-driven trade with high upside but equally high risk (clinical data + dilution). Not a long-term hold without confirmation.
#biotech #stocks #MCRB
